Type Size
Clinical Trials
Women Ages 18 and Above with Platinum Sensitive, Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Needed for Research Study
IRB-HSR# 13501
Service:
Cancer,
Women's Health
|
Category: Obstetrics/Gynecology
Adult Enrollment: Yes
|
Minor Enrollment: No
Primary Investigator: Susan Modesitt, M.D.
Contact Information
Contact: Heather Lothamer
Phone: 434.243.0315
E-mail: HLL5y@virginia.edu
Clinical Trial Description
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed By Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Fallopian Tube and Peritoneal Primary Cancer
UVA Health System, the Department of Obstetrics and Gynecology, the division of Gynecologic Oncology, seeks Women ages 18 and above with platinum sensitive, recurrent ovarian, fallopian tube, or primary peritoneal cancer for research study.
The purpose of the study is to compare the old treatment with the old treatment plus experimental drug, bevacizumab. Patients that are candidates for surgery will be randomly selected for surgery or to not have surgery before chemotherapy begins. Study involves taking an experimental medicine along with standard chemotherapy, blood draws, CT scans, urine tests and an EKG. Eligible patients will come to clinic for treatment for 6-8 visits every 3 weeks, each visit lasting 6-8 hours.
Compensation
No compensation is provided for this study.
